Latest Sarcoma Stories
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
PINEHURST, N.C., Jan.
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.
ReportsnReports.com adds “Rhabdomyosarcoma - Pipeline Review, H2 2014” to its store.
The publication of this latest power morcellator study follows warnings from U.S.
The new protocol comes amid deepening concerns that power morcellator procedures may result in the spread of undetected uterine cancers. New York, NY (PRWEB)
The Firm is evaluating power morcellator lawsuits on behalf of women who are also alleged to have experienced the spread of gynecological cancers due to uterine morcellation. New
NEW YORK, Dec. 10, 2014 /PRNewswire/ -- A new investigation by The Wall Street Journal has raised serious questions about the financial ties between certain U.S.
In the wake of FDA’s new morcellator cancer warning, a prominent medical group is questioning contraindications recommended by the agency. New York, New York
Agency Asks Power Morcellator Manufacturers to Add Boxed Warnings to Their Products Regarding Potential to Spread Undiagnosed Uterine Cancers New York NY (PRWEB)
Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...